Check out the companies making headlines in midday trading: Boeing , Lockheed Martin — Defense contractor Lockheed Martin sold off around 5.8% after Bloomberg News reported that President Donald Trump chose Boeing instead for a contract to create the next-generation fighter jet. Boeing shares surged about 3.1%. Nike — Shares tumbled 5.5% after the athletic retailer warned that sales would fall in the current quarter. That overshadowed a fiscal third-quarter report that exceeded expectations on both lines. Cleveland-Cliffs — The steel producer declined 1.2% after a report from the Minnesota Star Tribune said Cleveland-Cliffs would temporarily idle two factories, resulting in hundreds of job cuts. That decision comes as automakers have reduced orders amid uncertainty tied to President Donald Trump’s tariff policies. Lennar — Shares of the homebuilder tumbled 4% after it guided for 22,500 to 23,500 new orders for the fiscal second quarter, below the 23,802 consensus estimate, per StreetAccount. Lennar’s first-quarter earnings and revenue came above expectations. Micron Technology — The chipmaker dropped 8% even after posting better-than-expected earnings in the fiscal second quarter. Micron reported adjusted earnings of $1.56 per share on revenue of $8.05 billion, while analysts polled by LSEG expected $1.42 in earnings per share and $7.89 billion in revenue. FedEx — The parcel delivery firm saw shares tumbling more than 6% after the company cut its full-year profit and revenue forecasts . Chief Financial Officer John Dietrich cited continued weakness and uncertainty in the U.S. industrial economy, which is constraining demand for FedEx’s business-to-business services. Loop Capital downgraded FedEx following the news, calling it a “really bad recession stock.” Super Micro Computer — Shares of the semiconductor manufacturer advanced 7.8% after JPMorgan upgraded the stock to neutral from underweight. The investment firm cited a tailwind from a ramp in Blackwell shipments for the upgrade. Alnylam Pharmaceuticals — The biopharmaceutical stock jumped about 11.8% after the U.S. Food and Drug Administration approved its injectable drug, Amvuttra, to treat a rare and fatal heart disease. — CNBC’s Yun Li and Alex Harring contributed reporting.
Add A Comment
About Us
Our finance blog is your go-to resource for expert financial advice, covering everything from personal budgeting and saving strategies to smart investing and market analysis. Stay updated with the latest trends, tips, and insights to help you make informed decisions and achieve financial success.
Popular Post
© 2025 incapitalquest.com – All rights reserved.
About Us
Our finance blog is your go-to resource for expert financial advice, covering everything from personal budgeting and saving strategies to smart investing and market analysis. Stay updated with the latest trends, tips, and insights to help you make informed decisions and achieve financial success.
Popular Post
© 2025 incapitalquest.com – All rights reserved.